Nuo Therapeutics, Inc. Annual Report: A Performance Summary

I’ve put together this guide to help you understand how Nuo Therapeutics performed this year. My goal is to turn complex financial filings into clear information to help you decide if this company fits your investment goals.

---

1. What does this company do?

Nuo Therapeutics creates medical technology for chronic wound care. Their main product, the "Aurix System," is a device that uses a patient’s own blood platelets to create a healing gel. Doctors apply this gel to non-healing wounds, such as diabetic foot ulcers. By using the patient’s own biology, the system helps heal wounds that haven't responded to standard treatments.

2. How did they perform this year?

The company is in a growth phase. After restarting operations in 2021, they are gaining momentum. Revenue jumped from $1.4 million in 2024 to $3.1 million in 2025, a 121% increase. This growth is driven by an increase in wound care centers using the Aurix System and a successful new distribution strategy.

3. Major wins: The Smith+Nephew Deal

The biggest news is a distribution deal with Smith+Nephew, a global medical technology leader. Smith+Nephew now sells a version of the Aurix system under their own brand, giving Nuo instant access to a massive sales network. Nuo received a $1.5 million upfront fee in 2025 and is eligible for an additional $750,000 in 2026, contingent on hitting specific sales and insurance coverage targets.

4. Financial health: A tightrope walk

Despite the 121% revenue growth, Nuo is not yet profitable. They reported a loss of $4.2 million for 2025. As a small company with limited cash, they ended the year with $850,000. They currently spend about $350,000 per month and rely on raising capital through equity or debt to sustain operations.

5. Key risks for investors

If you are considering an investment, keep these factors in mind:

• Dilution: To cover their $4.2 million loss, the company frequently issues new shares. This increases the total share count, which reduces your ownership percentage and the value of your existing stake.
• Survival: With $850,000 in cash and a monthly burn rate of $350,000, the company has a limited runway. They must maintain consistent sales or secure additional funding to continue operations.
• Reimbursement: Their business model relies on Medicare and private insurance policies. While current payment rates are favorable, any changes in government or private insurance rules could impact profit margins.
• Concentration: A significant portion of their revenue depends on the Smith+Nephew partnership. If that relationship changes or if sales under that partnership underperform, Nuo may struggle to generate sufficient revenue on its own.

6. Future outlook

The company is focused on scaling the Aurix System through their partnership strategy. With established insurance payment rates, they aim to grow their active clinical sites by 30% by the end of 2026. This is a high-risk, high-reward scenario; success depends on reaching profitability before their current cash reserves are exhausted.

---

Final Thought for Investors: Nuo Therapeutics is at a critical juncture. While they have proven they can grow revenue and secure major partnerships, their current cash position is very lean. When evaluating this opportunity, ask yourself if you are comfortable with the high level of risk associated with their limited cash runway and the potential for further share dilution.